Articles
Ideas shaping biotechnology growth—commercial leadership, launch strategy, and rare disease insights from PharmaKonsult.
CAH Commercialization
Why commercial success for atumelnant will depend on diagnosis, market strategy, and commercial discipline—not pharmacology alone.
Read articleThe Eight Principles of Product Commercialization
A successful product launch begins long before FDA approval—commercialization is a series of strategic decisions that determine whether an innovative therapy reaches patients.
Read articleWhen Companies Buy More Than a Product
Lessons from the Immedica–Marinus acquisition on building a rare disease commercial platform—why infrastructure and capabilities can matter more than current product revenue.
Read articlePediatric Developmental & Epileptic Encephalopathies (DEE)
Commercial strategy for ultra-rare pediatric neurology—why success now depends on developmental outcomes, quality of life, and caregiver burden, not seizure reduction alone.
Read articleWhy Leadership Decisions Determine Commercial Success
Commercial success is rarely determined by the quality of the science alone—it is designed by leaders who make disciplined decisions long before launch.
Read articleCommercial Culture & Leadership
Scientific innovation discovers new possibilities. Leadership and culture determine whether those possibilities change patients' lives.
Read articleWhat Biotechnology Leaders Can Learn from Marinus Pharmaceuticals
A commercialization case study in rare disease strategy—why treated patients, not prevalence estimates, should drive commercial infrastructure and capital allocation.
Read articleBeyond the Science: How CEOs and Investors Should Evaluate Emerging Therapeutic Platforms
Using Sec61 as a case study in commercial decision-making—why the first indication, not the mechanism alone, often determines whether a platform becomes a successful enterprise.
Read article